SCHEMBL6080167

SCHEMBL6080167

O=C(O)c1cc(CCCO)c2cccc(O)c2n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.48
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
TSHR P16473 1/20 0.41
ALOX12 P18054 1/20 0.41
KDM4A O75164 2/20 0.39
RAB9A P51151 1/20 0.39
EGLN1 Q9GZT9 1/20 0.39
HIF1AN Q9NWT6 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
IGFBP3 P17936 2/20 0.39
IGFBP5 P24593 1/20 0.39
CCR6 P51684 1/20 0.38
PIM1 P11309 2/20 0.37
CYP1A2 P05177 1/20 0.37
BID P55957 4/20 0.37
MCL1 Q07820 4/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6080368 0.95 KDM4E (0.46) KDM4EKMT2AMEN1LMNATP53
SCHEMBL6080099 0.88 KDM4E (0.47) KDM4EKMT2AMEN1LMNATP53
Hydrochloric Acid SCHEMBL6080927 0.86 KDM4E (0.46) KDM4EKMT2AMEN1LMNATP53
SCHEMBL6079612 0.86 CYP4A11 (0.40) KDM4EKMT2AMEN1LMNATP53
SCHEMBL6080554 0.86 CYP4A11 (0.40) KDM4EKMT2AMEN1LMNATP53
SCHEMBL6080305 0.85 BID (0.56) KDM4EKMT2AMAPTBIDMCL1
SCHEMBL6605390 0.85 FDPS (0.38) KDM4EKMT2ATSHRIGFBP5
Hydrochloric Acid SCHEMBL6080849 0.84 FDPS (0.37) KDM4EKMT2ATSHRIGFBP5
SCHEMBL6079288 0.83 KDM4E (0.51) KDM4EKMT2AKDM4ARAB9AEGLN1
SCHEMBL6080477 0.80 NPC1 (0.48) KMT2AMEN1MAPTTSHRKDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US claimed
EP-1451159-A1 COMPOSITIONS DERIVED FROM QUINOLINE AND QUINOXALINE, PREPARATION AND USE THEREOF NEURO3D (FR) 2004-09-01 EP claimed
WO-2003010146-A1 COMPOSITIONS DERIVED FROM QUINOLINE AND QUINOXALINE, PREPARATION AND USE THEREOF NEURO3D (FR) 2003-02-06 WO claimed
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US disclosed
EP-1451159-A1 COMPOSITIONS DERIVED FROM QUINOLINE AND QUINOXALINE, PREPARATION AND USE THEREOF NEURO3D (FR) 2004-09-01 EP disclosed
WO-2003010146-A1 COMPOSITIONS DERIVED FROM QUINOLINE AND QUINOXALINE, PREPARATION AND USE THEREOF NEURO3D (FR) 2003-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NQO1, NQO2, RECQL KDM4E 1006/4885KMT2A 1384/4885MEN1 740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.